Real world study of bevacizumab in combination with chemotherapy, immunotherapy as first-line treatment of patients with advanced non-small cell lung cancer without EGFR mutation or ALK rearrangement
Latest Information Update: 31 May 2021
At a glance
- Drugs Antineoplastics (Primary) ; Bevacizumab (Primary) ; Immunotherapies (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 May 2021 New trial record
- 12 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research